FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies

European Journal of Pharmacology

Volumn 776, Issue , 2016, Pages 156-166

  Mashkani, Baratali ^a,b   Tanipour, Mohammad Hossein ^a   Saadatmandzadeh, Mohammad ^c   Ashman, Leonie K ^b   Griffith, Renate ^d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c FERDOWSI UNIVERSITY OF MASHHAD   (Iran)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Autophosphorylation inhibition; Cell proliferation inhibition; Docking; FLT3; GOLD; Small molecule kinase inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD135 ANTIGEN; CYSTEINE; DASATINIB; GLUTAMIC ACID; IMATINIB; LESTAURTINIB; MIDOSTAURIN; SUNITINIB; PROTEIN KINASE INHIBITOR;

ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EC50; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR MODEL; MUTANT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOUSE; MUTATION; PHOSPHORYLATION; PROTEIN DOMAIN;

ANIMALS; CELL LINE; CELL PROLIFERATION; FMS-LIKE TYROSINE KINASE 3; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MUTATION; PHOSPHORYLATION; PROTEIN DOMAINS; PROTEIN KINASE INHIBITORS;

EID: 84960806781     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.02.048     Document Type: Article

References (43)

1. S.E. Andersson, M.N. Svensson, M.C. Erlandsson, M. Dehlin, K.M. Andersson, and M.I. Bokarewa Activation of FMS-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis PLoS One 7 2012 e47668
2. S.A. Armstrong, A.L. Kung, M.E. Mabon, L.B. Silverman, R.W. Stam, M.L. Den Boer, R. Pieters, J.H. Kersey, S.E. Sallan, J.A. Fletcher, T.R. Golub, J.D. Griffin, and S.J. Korsmeyer Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification Cancer Cell 3 2003 173 183
3. S.A. Armstrong, M.E. Mabon, L.B. Silverman, A. Li, J.G. Gribben, E.A. Fox, S.E. Sallan, and S.J. Korsmeyer FLT3 mutations in childhood acute lymphoblastic leukemia Blood 103 2004 3544 3546
4. C.E. Carow, M. Levenstein, S.H. Kaufmann, J. Chen, S. Amin, P. Rockwell, L. Witte, M.J. Borowitz, C.I. Civin, and D. Small Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias Blood 87 1996 1089 1096
5. J.L. Cleveland, M. Dean, J.Y. Wang, A.M. Hedge, J.N. Ihle, and U.R. Rapp Abrogation of IL-3 dependence of myeloid FDC-P1 cells by tyrosine kinase oncogenes is associated with induction of c-myc Curr. Top. Microbiol. Immunol. 141 1988 300 309
6. S.W. Cowan-Jacob, H. Mobitz, and D. Fabbro Structural biology contributions to tyrosine kinase drug discovery Curr. Opin. Cell Biol. 21 2009 280 287
7. N. Daver, P. Strati, E. Jabbour, T. Kadia, R. Luthra, S. Wang, K. Patel, F. Ravandi, J. Cortes, X. Qin Dong, H. Kantarjian, and G. Garcia-Manero FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia Am. J. Hematol. 88 2013 56 59
8. T.M. Dexter, J. Garland, D. Scott, E. Scolnick, and D. Metcalf Growth of factor-dependent hemopoietic precursor cell lines J. Exp. Med. 152 1980 1036 1047
9. A. Eriksson, M. Hermanson, M. Wickstrom, E. Lindhagen, C. Ekholm, A. Jenmalm Jensen, A. Lothgren, F. Lehmann, R. Larsson, V. Parrow, and M. Hoglund The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia Blood Cancer J. 2 2012 e81
10. D. Fabbro, S. Ruetz, S. Bodis, M. Pruschy, K. Csermak, A. Man, P. Campochiaro, J. Wood, T. O'Reilly, and T. Meyer PKC412 - a protein kinase inhibitor with a broad therapeutic potential Anticancer Drug. Des. 15 2000 17 28
11. G.C. Fletcher, R.D. Brokx, T.A. Denny, T.A. Hembrough, S.M. Plum, W.E. Fogler, C.F. Sidor, and M.R. Bray ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action Mol. Cancer Ther. 10 2011 126 137
12. R. Foster, R. Griffith, P. Ferrao, and L. Ashman Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase J. Mol. Graph. Model. 23 2004 139 152
13. M.J. Frost, P.T. Ferrao, T.P. Hughes, and L.K. Ashman Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant Mol. Cancer Ther. 1 2002 1115 1124
14. K.S. Gajiwala, J.C. Wu, J. Christensen, G.D. Deshmukh, W. Diehl, J.P. DiNitto, J.M. English, M.J. Greig, Y.A. He, S.L. Jacques, E.A. Lunney, M. McTigue, D. Molina, T. Quenzer, P.A. Wells, X. Yu, Y. Zhang, A. Zou, M.R. Emmett, A.G. Marshall, H.M. Zhang, and G.D. Demetri KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients PNAS 106 2009 1542 1547
15. K.S. Gotze, M. Ramirez, K. Tabor, D. Small, W. Matthews, and C.I. Civin Flt3 high and Flt3 low CD34+progenitor cells isolated from human bone marrow are functionally distinct Blood 91 1998 1947 1958
16. J.D. Griffin Point mutations in the FLT3 gene in AML Blood 97 2001 2193A-2193A
17. J. Griffith, J. Black, C. Faerman, L. Swenson, M. Wynn, F. Lu, J. Lippke, and K. Saxena The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol. Cell 13 2004 169 178
18. N. Guex, and M.C. Peitsch SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling Electrophoresis 18 1997 2714 2723
19. K.M. Kampa-Schittenhelm, M.C. Heinrich, F. Akmut, H. Dohner, K. Dohner, and M.M. Schittenhelm Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms Mol. Cancer 12 2013 19
20. M. Levis, and D. Small FLT3: ITDoes matter in leukemia Leukemia 17 2003 1738 1752
21. M. Levis, and D. Small Small molecule FLT3 tyrosine kinase inhibitors Curr. Pharm. Des. 10 2004 1183 1193
22. W.H. Lin, W.T. Jiaang, C.W. Chen, K.J. Yen, S.Y. Hsieh, S.C. Yen, C.P. Chen, K.Y. Chang, C.Y. Chang, T.Y. Chang, Y.L. Huang, T.K. Yeh, Y.S. Chao, C.T. Chen, and J.T. Hsu BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML Br. J. Cancer 106 2012 475 481
23. B. Mashkani, R. Griffith, and L. Ashman Differences in growth promotion, drug response and intracellular protein trafficking of FLT3 mutants Iran. J. Basic Med. Sci. 17 2014 867 873
24. B. Mashkani, R. Griffith, and L.K. Ashman Colony stimulating factor-1 receptor as a target for small molecule inhibitors Bioorg. Med. Chem. 18 2010 1789 1797
25. B. Mashkani, A.F. Odell, E.M. Byrnes, R. Griffith, and L.K. Ashman Expression of biologically active human colony stimulating factor-1 in Pichia pastoris Protein Expr. Purif. 88 2013 93 97
26. S. Meshinchi, and F.R. Appelbaum Structural and functional alterations of FLT3 in acute myeloid leukemia Clin. Cancer Res. 15 2009 4263 4269
27. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, D.N. Scheibe, G.P. Snell, H. Zou, B.C. Sang, and K.P. Wilson Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J. Biol. Chem. 279 2004 31655 31663
28. C.D. Mol, K.B. Lim, V. Sridhar, H. Zou, E.Y. Chien, B.C. Sang, J. Nowakowski, D.B. Kassel, C.N. Cronin, and D.E. McRee Structure of a c-kit product complex reveals the basis for kinase transactivation J. Biol. Chem. 278 2003 31461 31464
29. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, F. Wang, L.T. Adrian, T. Zhou, W.S. Huang, Q. Xu, C.A. Metcalf 3rd, J.W. Tyner, M.M. Loriaux, A.S. Corbin, S. Wardwell, Y. Ning, J.A. Keats, Y. Wang, R. Sundaramoorthi, M. Thomas, D. Zhou, J. Snodgrass, L. Commodore, T.K. Sawyer, D.C. Dalgarno, M.W. Deininger, B.J. Druker, and T. Clackson AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
30. K.G. Roberts, A.F. Odell, E.M. Byrnes, R.M. Baleato, R. Griffith, A.B. Lyons, and L.K. Ashman Resistance to c-KIT kinase inhibitors conferred by V654A mutation Mol. Cancer Ther. 6 2007 1159 1166
31. R. Roskoski Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor Biochem. Biophys. Res. Commun. 356 2007 323 328
32. M.T. Rossner, G.A. McArthur, J.D. Allen, and D. Metcalf Fms-like tyrosine kinase 3 catalytic domain can transduce a proliferative signal in FDC-P1 cells that is qualitatively similar to the signal delivered by c-FMS Cell Growth Differ. 5 1994 549 555
33. C. Schubert, C. Schalk-Hihi, G.T. Struble, H.C. Ma, I.P. Petrounia, B. Brandt, I.C. Deckman, R.J. Patch, M.R. Player, J.C. Spurlino, and B.A. Springer Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors J. Biol. Chem. 282 2007 4094 4101
34. L. Shih, C. Huang, P. Wang, J. Wu, T. Lin, P. Dunn, and M. Kuo Acquisition of FLT3 or N-RAS mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia Leukemia 18 2004 466 475
35. P. Singh, J. Hoggatt, P. Hu, J.M. Speth, S. Fukuda, R.M. Breyer, and L.M. Pelus Blockade of prostaglandin E2 signaling through EP1 and EP3 receptors attenuates Flt3L-dependent dendritic cell development from hematopoietic progenitor cells Blood 119 2012 1671 1682
36. B.D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K.M. Murphy, T. Dauses, J. Allebach, and D. Small Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood 103 2004 3669 3676
37. E. Tamborini, S. Pricl, T. Negri, M.S. Lagonigro, F. Miselli, A. Greco, A. Gronchi, P.G. Casali, M. Ferrone, M. Fermeglia, A. Carbone, M.A. Pierotti, and S. Pilotti Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients Oncogene 25 2006 6140 6146
38. J. Tiesmeier, C. Muller-Tidow, A. Westermann, A. Czwalinna, M. Hoffmann, J. Krauter, G. Heil, A. Ganser, H. Serve, and W. Verbeek Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy Leuk. Res. 28 2004 1069 1074
39. J.S. Tokarski, J.A. Newitt, C.Y. Chang, J.D. Cheng, M. Wittekind, S.E. Kiefer, K. Kish, F.Y. Lee, R. Borzillerri, L.J. Lombardo, D. Xie, Y. Zhang, and H.E. Klei The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 66 2006 5790 5797
40. C. Ustun, D.L. DeRemer, A.P. Jillella, and K.N. Bhalla Investigational drugs targeting FLT3 for leukemia Expert Opin. Invest. Drugs 18 2009 1445 1456
41. E. Weisberg, C. Boulton, L.M. Kelly, P. Manley, D. Fabbro, T. Meyer, D.G. Gilliland, and J.D. Griffin Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 Cancer Cell 1 2002 433 443
42. K.A. Whartenby, P.A. Calabresi, E. McCadden, B. Nguyen, D. Kardian, T. Wang, C. Mosse, D.M. Pardoll, and D. Small Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease PNAS 102 2005 16741 16746
43. K.A. Whartenby, D. Small, and P.A. Calabresi FLT3 inhibitors for the treatment of autoimmune disease Expert Opin. Invest. Drugs 17 2008 1685 1692